NIH rolling out streamlined website to help public find information more easily

• Sanofi agreed to pay Regeneron $1 billion upfront and up to $7 billion in milestone payments to co-develop four drugs. • The two companies will split all development costs and future profits equally, with Sanofi managing global sales upon approval.

• Health equity reports from early October 2026 highlight gaps in lung cancer screening for people with HIV and barriers to allogeneic transplant access. • Lung cancer screening rates for people with HIV remain low even after eligibility for the tests tripled.

• The Pan American Health Organization (PAHO) held a briefing session on October 1, 2026, in Washington, D.C., to discuss accelerating the elimination of communicable diseases in the Americas. • The session focused on using national leadership and strategic investments to eliminate more than 30 communicable diseases and related health conditions.

• The World Health Organization released new Global Health Estimates on 2 October 2026 detailing health trends across countries and regions from 2000 to 2023. • Global life expectancy has returned to levels close to those seen before the COVID-19 pandemic.

• Health Secretary Robert F. Kennedy, Jr. and ARPA-H Director Alicia Jackson launched a project in Austin, Texas, to accelerate the clinical trial process. • The experimental program aims to reduce the total amount of time and money required to conduct medical trials.

• The FDA is allowing companies to conduct required safety and efficacy studies after their drugs and devices have already reached the market. • Agency records show that many of these postmarket studies are currently overdue or behind schedule.

• The FDA approved the first-ever therapies for four ultra-rare genetic and metabolic conditions, including Sanfilippo syndrome type A and Alexander disease, in September 2026. • These regulatory decisions also granted the first approved treatments for MCT8 deficiency and ataxia-telangiectasia.

• NanoViricides, Inc. filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2026, with the Securities and Exchange Commission on September 28, 2026. • The company is currently conducting Phase II clinical trials for NV-387, a broad-spectrum antiviral designed to treat difficult viral infections.

• Health officials and a hospital director confirmed a new case of mpox in Bunia, a city in northeastern Congo. • The region is already managing an Ebola epidemic that has infected 7,890 people and caused 3,799 deaths since May 15.

• Regeneron and Sanofi expanded their antibody partnership to develop new treatments, with Sanofi paying $1 billion upfront. • The companies plan to move three specific antibodies into clinical studies by 2027, with future profits split 50:50.

• The Pan American Health Organization recognized five countries and territories in the Americas on September 29, 2026, for successfully eliminating specific diseases over the past year. • These achievements contribute to a broader regional target to eliminate more than 30 communicable diseases, which are illnesses that spread from one person to another, by 2030.